BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.)
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes / L. A. Michael, B. Kirstine, C. Helen M., D. John, E. Scott S., E. Sille, H. Søren, H. G. Kees, K. Steven E., K. Robert F., L. Ildiko, O. Tugce K., M. Marie M., P. Jorge, T. Christoffer W., Ryan, D. H., A. Porto, A. Villarino, C. Chacon, C.J. Zaidman, E. Farias, E. Duronto, J.M. Farias, M. Casas, A. Oviedo, H.D. Sanabria, P. Perez Terns, J. Amerena, M. Leung, D.M. Colquhoun, P. Purnell, M. William, W.P. Abhayaratna, C. Morbey, S. Nicholls, D. Cross, M. Arstall, K. Kostner, M. Shirazi, E.I. Ekinci, H. Toplak, U. Hanusch, E. Aigner, B. Ludvik, A. Kautzky-Willer, R. Prager, S. Kaser, P. Vanduynhoven, J. Verwerft, M. Vrolix, M. De Pauw, C. Vercammen, P. Van De Borne, Z.R. Prakova-Teneva, N. Runev, I. Petrov, M. Milanova, A. Postadzhiyan, V. Gelev, S.P. Vasileva, B. Georgiev, T. Katova, M. Tokmakova, A. Goudev, D. Vassilev, D.A. Minkova, S. Tisheva-Gospodinova, Y. Yotov, P. Rossi, J.C. Nicolau, L.N. Maia, J.F. Saraiva, A.P. Kormann, F.B. Arantes, S.E. Kaiser, S.O. Leite, C. Cercato, A.G. Fonseca, H.R. Kurtz Lisboa, L.A. Turatti, D.R. Franco, P.S. Farsky, L.E. Ritt, P. Poirier, A.S. Pandey, F. St-Maurice, R. Bourgeois, Y. Robitaille, C. Constance, P. Filteau, S. Verma, R. Vijayaraghavan, J. Weisnagel, A. Egan, M. Hartleib, S. Pedersen, G. Tellier, K. Peters, J.Y. Cha, M.F. Langlois, N. Garg, S. Datta, T. Salter, T. Spaic, D. Lau, G.M. Tsoukas, J. Stewart, N. Vale, R. Rabasa-Lhoret, G. Vallieres, R. Allison, C.A. Martinez Cano, J.L. Accini Mendoza, R. Botero Lopez, M.A. Urina Triana, J.A. Rodriguez Plazas, A.J. Cadena Bonfanti, J. Malecha, Z. Klimsa, A. Linhart, P. Koleckar, O. Cermak, L. Kuchar, J. Stasek, E. Malicherova, A. Vesela, M. Haluzik, W. Jungmair, H.D. Stahl, K.F. Appel, A. Al-Zoebi, H. Eggebrecht, J. Wagner, H. Zeller, K. Kreutzmann, S. Meyhöfer, C. Von Engelhardt, J. Sauter, S. Jacob, K. Sturm, G. Kahrmann, C. Von Münchhausen, J. Chevts, A. Hagenow, M. Froer, A. Segner, M. Lehrke, T. Schaum, P. Heymer, U. Wendisch, H.P. Kempe, R.J. Denger, J. Steindorf, M. Bøttcher, M. Mæng, G. Gislason, K. Egstrup, J.D. Hove, S.E. Jensen, D.E. Nibouche, M. Chettibi, N. Hammoudi, F. Tinahones, C. Morales Portillo, C. De La Cuesta, A. Soto González, M. Rivas Fernández, A. Castro, O. González Albarrán, P. Mezquita Raya, C. De Pablo, J.F. Merino Torres, L. Masmiquel Comas, T. Lakka, P. Ahtiainen, M. Pietilä, E. Ilveskoski, O. Ukkola, L. Niskanen, T. Keski-Opas, B. Cariou, T. Demicheli, C. Petit, M. Kerneis, F. Schiele, J.F. Thuan, B. Gatta-Cherifi, B. Verges, J.S. Hulot, D. Stephan, P. Serusclat, G. Steg, G. Barone Rochette, P. Keeling, T. Sathyapalan, H. Randeva, Y.K. Wong, A. Miras, P. Clifford, D. Tatovic, R. Andrews, A. Strzelecka, N. Asamoah, M. Barber, A. Broadley, K. Lee, N. Paul, B. Vaidya, N. Wyatt, H. Price, R. Vincent, J. Wakeling, R. Clark, S. Creely, P. English, S. Sharma, M. Capehorn, C. Lang, Y. Beerachee, R. Sharma, J. Wilding, P. Wilson, M. Lynch, B. Mcgowan, M. Myint, C. Dang, J. Khoo, R. Senior, N. Swanson, S. Bellary, S. Nair, J. Stoker, S. Dobson, E. Jackson-Voyzey, G. Tait, A. Kartalis, E. Tsougos, S. Patsilinakos, K. Tziomalos, V. Lambadiari, A. Kokkinos, G. Argyrakopoulou, L. Lanaras, E. Liberopoulos, G. Siasos, K. Stamatelopoulos, G. Ntaios, E. Pagkalos, A. Ruzic, I. Kruljac, D. Milicic, S. Canecki Varzic, H. Budincevic, K. Fuckar, D. Delic-Brkljacic, D. Páll, G. Lupkovics, A. Piros, L. Könyves, R. Takács, M. Baranyai, P. Desai, A. Abhyankar, K.M. Parvathareddy, D.K. Agarwal, S. Jitendra Pal Singh, R. Sethi, G.S. Wander, K.G. Prafulla, D. Desai, U. Kaul, V. Vijan, N. Thomas, J. Christopher, S. Hiremath, A. Bhagwat, S. Bansal, A. Mahajan, S. Mittal, N. Ajay, R.K. Abhaichand, M. Fulwani, S. Garg, D. Gandotra, M.K. Shah, D. Kahali, K. Varghese, R.B. Pothineni, J. Arneja, R. Ambuj, J. Kannan, V. Maher, M. Byrne, S. Sreenan, D. Molony, C. Le Roux, K. Mcdonald, R. Durst, M. Shechter, Y. Arbel, N. Shehadeh, T. Zornitzki, Y. Sofer, I. Liberty, V. Vishlitzky, O. Mosenzon, A. Bashkin, G. Segal Lieberman, D. Dicker, F. Santini, F. Leonetti, S. Buscemi, G. Mingrone, U. Pagotto, A. Malavazos, D. Tuccinardi, G. Cogni, S. Bo, E. Mannucci, P. Sbraccia, L. Frittitta, M.C. Zatelli, M. Bucci, C. Berra, R. Vettor, F. Dotta, F. Cortinovis, A.M. Colao, M. Mirani, F. Muratori, M. Manita, M. Doi, F. Oh, A. Sato, Y. Takeuchi, A. Sueyoshi, Y. Hata, N. Miyamoto, K. Fujii, S. Mitomo, K. Hanaoka, Y. Okada, H. Ezaki, I. Maeda, M. Kawanishi, R. Kitamura, T. Miyake, A. Kiyosue, Y. Fukushima, T. Isawa, A. Watanabe, O. Ueda, H. Kunishige, Y. Ono, T. Kadokami, T. Iwasawa, H. Onaka, T. Sugiura, N. Kinoshita, T. Ando, M. Oguri, T. Matsumoto, T. Kato, T. Koga, R. Fujita, H. Yamaguchi, H. Teragawa, K. Morisaki, M. Yamasaki, H. Okayama, T. Nagano, M. Abe, H. Tanaka, M. Natsuaki, T. Sakamoto, M. Ohsugi, H. Maeda, S. Kodera, M. Kinoshita, I. Klavina, A. Lace, G. Latkovskis, I. Rezgale, G. Rancane, I. Veze, D. Teterovska, I. Sime, P.A. Garcia Hernandez, R. García Reza, M.A. Arias Mendoza, J.L. Arenas León, A.E. Bazzoni Ruiz, E.C. Morales Villegas, J.R. Lazcano Soto, S.A. Jimenez-Ramos, M.O. De Los Rios Ibarra, T.K. Ong, I.B.Z. Abidin, S.S. Kasim, N. Ali, W.M.I. Wan Mohamed, L.Y. Lee, S. Krishinan, A.I. Ruhani, Z. Hussein, A. Rosman, L.H. Bang, C. Van Der Zwaan, T. Vossenberg, F.M.A.C. Martens, B. Groenemeijer, P. Nierop, R. Dorman, A.P. Van Beek, H. Swart, J. Schaap, T.J. Römer, H.O. Høivik, S. Tonstad, J. Hjelmesaeth, L. Gullestad, O.K. Nygård, R.G. Høgalmen, E. Rice, S. Halvorsen, T. Gretland Valderhaug, W. Czochra, I. Wozniak, P. Bogdanski, E. Franek, L. Ostrowska, G. Kania, A. Karczmarczyk, G. Gajos, B. Stogowska-Nikiciuk, W. Chrustowski, G. Skoczylas, J. Jurowiecki, M. Kujawiak, A. Leksycka, E. Szyprowska, M. Beckowski, P. Kalmucki, M. Lukaszewicz, G. Pulka, M. Jozefowska, P. Monteiro, S. França, L. Fonseca, C. Martins, F. Pinto, D. Ferreira, D. Enculescu, L. Marin, C. Constantin, G. Enache, M. Morosanu, D.V. Reurean Pintilei, C.V. Mistodie, S. Constantinescu, G. Nicolescu, A. Onaca, V. Nafornita, L. Pop, A. Cif, B. Popa, D. Cosma, M. Kurtinecz, C. Toarba, S. Lupu, E. Caceaune, N.M. Mîndrescu, N. Hancu, I.M. Vladu, R. Avram, C.V. Badiu, A. Vlad, P. Ermakova, O. Barbarash, D. Ruyatkin, M. Ezhov, V.V. Ryabov, K. Zrazhevskiy, M.Y. Sergeeva-Kondrachenko, I. Gurieva, Z. Kobalava, M. Zykov, L. Khaisheva, I.G. Gordeev, E.A. Zhdanova, R. Sardinov, A. Zalevskaya, A.A. Boshchenko, E. Shutemova, Y. Samoilova, T.A. Lysenko, M. Sorokin, L.A. Suplotova, O.O. Bolshakova, I.V. Dvoryashina, O. Smolenskaya, N.G. Veselovskaya, L. Belousova, E. Antonova, A.B. Peskov, O. Shaydyuk, T. Markova, A. Obrezan, T. Sveklina, S. Shalaev, O. Gilinskaya, T. Khlevchuk, A. Galyavich, V. Mareev, G.N. Guseva, O. Zagrebelnaya, O. Vorobyeva, I. Krivosheeva, D. Alpenidze, G. Platonov, O. Vinogradova, Y. Pergaeva, E.E. Kazakova, I. Ipatko, O. Ershova, M. Kharakhulakh, N. Lalic, G. Stankovic, A. Ristic, N. Djenic, E. Stokic, K. Lalic, M. Asanin, M. Vukicevic, B. Eliasson, L. Rydén, K. Eliasson, C.J. Lindholm, H. Holmer, T. Mooe, D. Piyayotai, C. Udommongkol, P. Vathesatogkit, A. Suwanagool, S. Kiatchoosakun, S. Suwanwalaikorn, N. Sansanayudh, S. Buranapin, W. Wongcharoen, O.S. Bakiner, A. Celik, R. Sari, Y. Altuntas, M. Kayikcioglu, D. Gogas, E. Ozpelit, M.M. Tuna, M. Araz, A. Oguzhan, I. Gul, O. Ozdogan, M. Unubol, Y.A. Sonmez, S. Sancak, M. Adas, M. Kanadasi, S. Dagdelen, D. Yazici, O. Soyluk Selcukbiricik, M.E. Liu, C.C. Wu, H.I. Yeh, I.C. Hsieh, T.L. Lee, L. Rudenko, G. Myshanych, O. Parkhomenko, T. Ilashchuk, I. Vyshnyvetskyy, V. Leonidova, O. Horoshko, O. Buriakovska, V. Velychko, M. Kushnir, M. Stanislavchuk, Y. Kyyak, L. Todoriuk, O. Levchenko, Z. Lysak, Y. Mostovoy, H. Serota, J.A. Doran, M. Concha, S. Lupovitch, S. Fordan, A.K. Samal, C.V. Desouza, N. Rasouli, S.K. Smith, A. Shneker, B. Harris, D. Kandath, A. Alkaradsheh, W. Clark, J. Carr, R.J. Anderson, H. Tran, M.F. Jardula, S.P. Marso, P. O'Donnell, B. Snyder, A. Wynne, M.J. Koren, K. Harris, J.B. Buse, I. Lingvay, R. Murray, B.P. Swenson, F. Bitar, N. Singh, J. Wallace, K. Cannon, A. Murthy, W. Bakdash, B. Iteld, T. Logemann, R. Busch, M. Correia, L. Usdan, M. Bernstein, D. Jabbar, F. Mcgrew, S. Sultan, D.C. Allison, W.T. Garvey, J. Zacher, K. Sivalingam, D. Robbins, V.R. Aroda, D. Brautigam, R.A. Jackson, T.H. Riley, R. Sangrigoli, S. Baum, R.E. Mills, C.R. Reyes, E.J. Morawski, H. Abou Assi, M. Berk, D. Tripathy, L. Billings, M. Lewis, E. Hewitt, S. Zarich, M. Ariani, I.A. Siddiqui, D.D. Mcpherson, W. Herzog, P. Levins, J. Soufer, R. Carrillo-Jimenez, I. Pereira, N.Y. Daboul, N. Buljubasic, S.A. Geller, G. Rosen, H.S. Wenocur, H. Audish, A. Dela Llana, W.C. Biggs, C.V. Calinescu, M. Agha, S.K. Brodie, H.E. Bays, M.J. Budoff, R. Kastelic, G.N. Ledesma, B.K. Mclean, T. Powell, A. Sathananthan, F. Sigal, J.P. Wilson, J. Lash, J. Sidey, R. Buynak, E.S. Pereira, O. Barnum, B. Burguera, J.M. Joyce, B.M. Nayak, T. Lenzmeier, E. Siraj, M.L. Warren, H. Weintraub, C.E. Dukes, P.M. Houser, D.J. Kereiakes, H. Lofton, M.A. Raikhel, B. Weber, P.J. Opsahl, B. Block, I. Beshay, S. Khadra, A.P. Brockmyre, W.H. Gandy, J.A. Risser, N.A. Jaffrani, C. Sotolongo, B. Heimer, A. Iranmanesh, A.A. Arif, C.F. Lovell, A. Philis-Tsimikas, J.C. Garza, R.P. Potu, N. Shah, D. Spriggs, J.M. Agaiby, J. Liu, R.S. Purighalla, J.B. Oaks, S. Saggar, M.B. Patel, M. Qureshi, R. Solano, J. Scott, G.M. Cornett, N. Lepor, S.N. Nakhle, G. Miller, R. Pop-Busui, A. Trusau, H.C. Shea, R.S. Call, A.N. Hartman, J. Condit, J. Pullman, H.W. Rodbard, C. Martinez, J.G. Geohas, M. Issa, C.W. Sofley, T. Chaicha-Brom, K. Ward, R. Lorraine, A. Ghazi, E.J. Klein, D. Klonoff, S. Ong, A. Vo, L.J. Aronne, M.L. Gambill, A. Bhan, W. Sargeant, C. Still, R.P. Morin, M. Delibasic, C.F. Breton, E.A. Perez-Vargas, P. Oneil, H. Bosworth, M.P. Gilbert, O. Ruffin, E.M. Folkens, P. Meyers, C. Wierum, A. Jastreboff, A.K. Davuluri, A. Ahmed, S.C. Gorton, M.P. Finneran, L. Herman, T. Jerkins, I. Munir, A. Tamirisa, B. Curtis, T. Kubicki, W. Johnson, Q. Yuan, S.S. Krishnasamy, J. Welker, S. Chandra, B. Buffman, A. Perkelvald, R.E. Pratley, Y. Shlesinger, J. Poremba, L.J. Levy, R. D'Agostino, K. Friedman, I.O. Ebrahim, A. Badat, L. Burgess, N. Fourie, D. Urbach, M. Fulat, E. Van Nieuwenhuizen, N. Tsabedze, K. Coetzee, E. Klug, E.M. Makotoko, N. Moosa, D.M. De Jong, E. Van Der Walt, L. Van Zyl, C. Corbett, C. Kapp, S. Wadvalla, S.Y. Dawood, Z.E. Punt, L. Lombard, J.J. Lombaard, V.N. Bandezi, J. Peter, P. Jugnundan. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 389:24(2023), pp. 2221-2232. [10.1056/nejmoa2307563]
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Malavazos;
2023
Abstract
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.)| File | Dimensione | Formato | |
|---|---|---|---|
|
NEJMoa2307563.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
551.77 kB
Formato
Adobe PDF
|
551.77 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




